• LAST PRICE
    6.2900
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.1587%)
  • Bid / Lots
    6.2500/ 1
  • Ask / Lots
    6.4400/ 3
  • Open / Previous Close
    6.3200 / 6.3000
  • Day Range
    Low 6.0200
    High 6.3500
  • 52 Week Range
    Low 2.6800
    High 8.2212
  • Volume
    289,003
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 6.3
TimeVolumeCAPR
09:32 ET106416.3
09:34 ET1006.26
09:38 ET2006.273
09:43 ET1006.32
09:45 ET3006.32
09:50 ET1506.3025
09:56 ET1006.34
09:59 ET14676.27
10:01 ET18006.25
10:03 ET63746.23
10:06 ET119316.145
10:08 ET34106.205
10:10 ET14416.18
10:15 ET22006.17
10:17 ET6006.14
10:19 ET3006.13
10:24 ET2006.155
10:26 ET1006.14
10:28 ET4016.17
10:30 ET3526.21
10:32 ET8426.2
10:39 ET1646.22
10:42 ET13786.15
10:46 ET1006.13
10:50 ET2126.1512
10:51 ET1006.16
10:53 ET45576.13
10:55 ET7016.12
10:57 ET2006.14
11:06 ET1006.145
11:13 ET3596.145
11:20 ET1006.14
11:22 ET8836.12
11:24 ET2006.12
11:27 ET1006.12
11:31 ET1006.12
11:38 ET22106.13
11:49 ET22006.14
11:51 ET1006.14
11:54 ET66176.1
11:56 ET9006.095
12:02 ET8106.12
12:03 ET9956.1
12:05 ET1006.11
12:07 ET3406.11
12:09 ET8546.12
12:12 ET5006.1187
12:14 ET50536.09
12:16 ET86806.12
12:18 ET35676.175
12:20 ET6006.175
12:21 ET9976.205
12:23 ET1616.2114
12:27 ET11066.225
12:30 ET4006.225
12:32 ET4006.225
12:34 ET3006.225
12:36 ET71716.305
12:38 ET91086.24
12:39 ET10006.2799
12:41 ET2006.22
12:52 ET3006.2001
12:56 ET1336.2072
12:59 ET3006.225
01:01 ET21006.225
01:06 ET3006.23
01:08 ET3006.23
01:10 ET1006.225
01:12 ET2006.225
01:14 ET4006.225
01:17 ET3006.225
01:21 ET2006.22
01:24 ET11006.24
01:26 ET2006.235
01:28 ET3346.25
01:30 ET186746.215
01:32 ET64266.25
01:33 ET213626.21
01:35 ET58766.16
01:37 ET5006.17
01:39 ET3006.15
01:44 ET17566.12
01:46 ET1006.11
01:48 ET1006.12
01:50 ET145296.03
01:51 ET2006.095
01:53 ET3006.08
01:55 ET27476.06
01:57 ET1006.09
02:00 ET3006.085
02:02 ET1006.09
02:04 ET23276.115
02:08 ET2006.12
02:09 ET8006.135
02:11 ET1006.135
02:13 ET12596.12
02:15 ET1006.13
02:18 ET1006.13
02:20 ET3006.13
02:22 ET4006.15
02:24 ET11106.16
02:26 ET1006.165
02:27 ET1006.175
02:29 ET8006.175
02:31 ET3076.1615
02:33 ET6296.22
02:36 ET5006.2231
02:38 ET14006.205
02:40 ET74676.17
02:42 ET2006.17
02:44 ET1976.18
02:45 ET2006.18
02:47 ET1006.18
02:49 ET2006.18
02:51 ET15006.19
02:58 ET1006.21
03:00 ET8756.23
03:02 ET22066.23
03:05 ET1006.25
03:09 ET1006.25
03:14 ET10006.25
03:16 ET1006.25
03:20 ET9986.23
03:21 ET9006.24
03:23 ET1006.24
03:25 ET4046.26
03:27 ET21806.23
03:34 ET4006.25
03:36 ET3006.25
03:38 ET5006.25
03:39 ET9516.2443
03:41 ET13346.25
03:43 ET15556.25
03:45 ET5006.25
03:48 ET20686.26
03:50 ET4006.27
03:52 ET8986.29
03:54 ET10506.3
03:56 ET31486.31
03:57 ET34976.295
03:59 ET53466.29
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCAPR
Capricor Therapeutics Inc
200.4M
-7.2x
---
United StatesCLLS
Cellectis SA
207.5M
-1.5x
---
United StatesFENC
Fennec Pharmaceuticals Inc
199.7M
194.7x
---
United StatesHOWL
Werewolf Therapeutics Inc
207.7M
-4.6x
---
United StatesMDWD
Mediwound Ltd
164.5M
-22.4x
---
United StatesQURE
Uniqure NV
235.5M
-0.8x
---
As of 2024-05-21

Company Information

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Contact Information

Headquarters
8840 Wilshire Blvd, 2nd FloorBEVERLY HILLS, CA, United States 90211
Phone
310-358-3200
Fax
302-655-5049

Executives

Executive Chairman of the Board
Frank Litvack
President, Chief Executive Officer, Director
Linda Marban
Chief Financial Officer
Anthony Bergmann
Executive Vice President, General Counsel
Karen Krasney
Director
Paul Auwaerter

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$200.4M
Revenue (TTM)
$27.1M
Shares Outstanding
31.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.99
EPS
$-0.88
Book Value
$0.73
P/E Ratio
-7.2x
Price/Sales (TTM)
7.4
Price/Cash Flow (TTM)
---
Operating Margin
-96.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.